Boehringer, moved to Milan from Reggello. Merck either sells or closes down in Pavia

Boehringer, si trasferisce a Milano l’ultima divisione rimasta a Reggello. Si conclude una storia lunga quasi mezzo secolo

Il reparto Chc della Boehringer lascerà Reggello entro giugno e verrà completamente trasferito a Milano. E’ l’ultima divisione rimasta in questi anni in Valdarno della multinazionale farmaceutica di Ingelheim. 34 dipendenti ancora occupati: accordo con i sindacati in via di definizione. Domani in programma l’incontro con l’azienda. Si chiude una storia lunga 40 anni.

Data della notizia:  25.11.2014 – di Eugenio Bini – valdarnopost

Addio Boehringer. La divisione Chc. l’ultima rimasta, si appresta a lasciare il Valdarno entro giugno 2015. Attualmente occupa 34 dipendenti.

Il reparto dei farmaci senza obbligo di prescrizione medica è l’ultimo rimasto attivo a Prulli. Fino al 2011 la multinazionale tedesca occupava più di 400 dipendenti. Poi venne dato avvio al trasferimento a Milano mentre già nel 2009 l’Istituto De Angeli,  il reparto produttivo dell’azienda – che attualmente occupa lo stabilimento – venne venduto alla multinazionale francese Fareva.

Così della vecchia realtà Boehringer era rimasto il reparto informatico – di una società dell’empolese – e la divisione Chc, dei farmaci da banco, mentre quattro persone continuano a lavorare per la multinazionale farmaceutica attraverso il telelavoro.

Nelle scorse settimane Boehringer ha comunicato l’intenzione di chiudere anche il reparto Chc e di trasferire il personale a Milano. Un’operazione che verrà portata a compimento a scaglioni entro giugno 2015.

The union dispute has been opened, as Alessandro Picchioni of Filctem CGIL points out. A new meeting between the company and the unions has been scheduled for tomorrow.

Finisce così una storia – quella che lega la multinazionale di Ingelheim sul Reno a Reggello –  lunga più di 40 anni.

«Merck sale, it takes time»

The appeal of workers and institutions, the company opens but the ok from the parent company is needed. Summit in Rome

di Anna Ghezzi – 25 novembre 2014 – la Provincia Pavese

PAVIA. While Merck, understood as the American pharmaceutical giant, buys commercial rights to NewLink Genetics Corp's experimental Ebola vaccine for €50 million plus royalties, the 184 workers of the Merck plant in Pavia are still suspended between the closure of the plant with no ifs and buts and the possibility that another buyer will arrive after the failure of the negotiations with Zambon. The negotiation with the Vicenza-based company is closed, no glimmer on the horizon: the confirmation arrived yesterday morning at the meeting convened by the prefect Giuseppa Strano Materia at the request of the trade union organisations. The window until 31 March has been confirmed: the closure of production in via Emilia is delayed by three months. But selling in four months seems impossible, which is why the request for more time has come from the table. A few more months. The answer will come directly to the table requested of the Ministry of Economic Development, but the last word belongs to the US parent company.

There were more than twenty at that table yesterday morning: the mayor Massimo Depaoli and the councilor Davide Ottini, the president of the province Daniele Bosone and the councilor Francesco Brendolise, a representative of the Region (absent however the councilor Mario Melazzini), the president of Confindustria Francesco Caracciolo, the unitary trade union representatives and the confederal trade unions (Renato Losio and Giorgio Mercuri for the CGIL, Gianni Ardemagni for the CISL, Carlo Barbieri and Pietro Cavallaro for the UIL). But there were also Giovanni Parisi, personnel manager, Goffredo Freddi, institutional relations, and Stefano Verona, director of the plant in via Emilia. «Merck highlighted the reasons for the interruption of the negotiations with Zambon – explains Ottini – or rather for differences with respect to what was agreed in the letter of intent at the end of August. Zambon allegedly made other demands that Merck was unwilling to fully satisfy. The negotiation is formally closed, the plant back on the market. We will have a table at the development ministry by mid-December». «I think it is positive that institutions and social partners are pushing Merck to consider alternative industrial and occupational solutions to Zambon – explains Ardemagni, Femca -. To promote this objective, it is necessary for the plant to remain productive for the time necessary to implement it». We will save some time given that all the dossiers are already ready – says Mercuri, Filctem – and that we will start from the agreement reached with Zambon. We appreciated the sensitivity of the institutions united to find a solution: to do so, however, Merck must give more time". "We ask the company to do everything to find a new buyer - underlines Barbieri, Uil - and having more time is essential". "We all hoped that with Zambon a solution would be reached for the Merck case - concludes Caracciolo, Industriali - We will do our part to find new investors, the attractiveness of the entire territory is at stake". And the future of over 500 families, if we also count the related pharmaceutical industries which produced 2.7 billion tablets a year.